In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548.
OBJECTIVE
A novel [(68)Ga]-labeled DOTA-4-amino-1-carboxymethyl-piperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 peptide (BAY86-7548) having high affinity to bombesin receptor subtype II to detect primary and metastatic prostate carcinoma using positron emission tomography/computed tomography (PET/CT) was synthesized and evaluated for prostate cancer.


METHODS
In this first human study with BAY86-7548, 14 men scheduled for radical prostatectomy (n = 11) or with biochemical recurrence after surgery or hormonal therapy (n = 3) were enrolled. The patients received an intravenous injection of BAY86-7548 followed by over 60-minute dynamic imaging of prostate gland (n = 10) and/or subsequent whole-body imaging (n = 14). The visual assessment of PET/CT images included evaluation of intraprostatic (12 subsextants) and pelvic nodal uptake of BAY86-7548 in 11 surgical patients and detection of potential metastatic foci in all patients. In patients with biochemical recurrence, results were compared with those of either [(11)C]-acetate (n = 2) or [(18)F]-fluoromethylcholine (n = 1) PET/CT.


RESULTS
We found a sensitivity, specificity, and accuracy of 88%, 81% and 83%, respectively, for detection of primary PCa and sensitivity of 70% for metastatic lymph nodes using histology as gold standard. BAY86-7548 correctly detected local recurrence in prostate bed and showed nodal relapse in accordance with [(11)C]-acetate PET/CT in 2 patients with biochemical relapse. In the third hormone refractory patient, BAY86-7548 failed to show multiple bone metastases evident on [(18)F]-fluoromethylcholine PET/CT.


CONCLUSIONS
BAY86-7548 PET/CT is a promising molecular imaging technique for detecting intraprostatic prostate cancer.
Authors' Affiliations: Department of Surgery, Division of Urology, Departments of Clinical Physiology and Nuclear Medicine, Oncology and Radiotherapy, and Pathology, Turku University Hospital; Turku PET Centre; Department of Diagnostic Radiology, University of Turku, Turku, Finland; Departments of Medical Oncology and Nuclear Medicine, University Hospital of Zurich; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland; Bayer Pharma AG, Berlin, Germany.
Esa
E
Kähkönen
Ivan
I
Jambor
Jukka
J
Kemppainen
Kaisa
K
Lehtiö
Tove J
TJ
Grönroos
Anna
A
Kuisma
Pauliina
P
Luoto
Henri J
HJ
Sipilä
Tuula
T
Tolvanen
Kalle
K
Alanen
Jonna
J
Silén
Markku
M
Kallajoki
Anne
A
Roivainen
Niklaus
N
Schäfer
Roger
R
Schibli
Martina
M
Dragic
Anass
A
Johayem
Ray
R
Valencia
Sandra
S
Borkowski
Heikki
H
Minn
D000368:Aged; D000369:Aged, 80 and over; D001839:Bombesin / Q000031:analogs & derivatives; D005710:Gallium Radioisotopes; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011471:Prostatic Neoplasms / Q000175:diagnosis*; D012008:Recurrence; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed
D005710:Gallium Radioisotopes; D001839:Bombesin